- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07311213
GENI E AUTISMO - IPSC (IPSC)
ESPLORAZIONI CELLULARI - CELLULE PLURIPOTENTI INDOTTE DA SOGGETTI CON DISTURBO DELLO SPETTRO AUTISTICO, DAI LORO FAMILIARI E DA CONTROLLI
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by deficits in social interaction and verbal and non-verbal communication (DSM-5, 2013), affecting approximately 2% of the general population. In 5 to 40% of cases, genetic factors are identified as the cause of these disorders, with prevalence depending on the technique used (exomes and/or SNP arrays) and the associated intellectual deficit. In the majority of cases, the etiology remains unknown. Studies of microdeletions/microduplications (copy number variants) or Whole Exome Sequencing and Whole Genome Sequencing (Single Nucleotide Variants) show the involvement of numerous genes in the predisposition to autism. ASD remains a genetically heterogeneous disorder, as more than 250 genes have been associated with ASD to date.
The main objective of the project is to continue identifying genetic factors, and also to understand the biological mechanisms involved in the emergence of autistic symptoms.
Identifying biological pathways is an essential step in developing new therapeutic strategies. In addition, one of the major challenges of this study is to better understand the phenotype/genotype relationships in ASD. This requires in-depth knowledge of the phenotypic characteristics of participants with ASD and their families, as well as neurotypical populations. This study combines the scientific expertise of researchers specializing in molecular biology, phenotypic exploration (clinical, cognitive, MRI, EEG, biochemistry, immunology), and the use of pre-therapeutic cellular models (iPSCs, neural precursors, organoids).
The objective of this work is the identification of numerous genes associated with ASD and involved in synaptic formation and regulation: NLGN3-4, SHANK1 and SHANK3, CNTN-6, and CNTNAP4. This work was combined with in-depth phenotypic explorations of ASD participants and their relatives. It has made it possible to clarify the neuroanatomical characteristics of participants with ASD and their genetic substrate, as well as the underlying cognitive processes.
All of this work opens up new prospects for identifying new therapeutic targets using preclinical cell models (IPSCs Induced pluripotent stem cells, neural progenitors, organoids) developed in particular by I-Stem and Human Technopole.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
- Aim 1 : To clarify the biological mechanisms associated with genetic variations identified in participants with ASD by studying dedifferentiated cells transformed into induced neurons or organoids. This objective will be achieved using a population of individuals with ASD, a population of relatives and a population of controls.
- Aim 2 : To study the cellular mechanisms affected by the presence of abnormalities identified in participants with ASD. The use of pluripotent cells differentiated into neurons or organoids is a major tool for understanding the pathophysiology of cell development and pathways in autism. These derived neurons are an indispensable proxy for the biological understanding of ASD.
- Aim 3 : To identify new therapeutic approaches, by using pluripotent cells and organoids to perform high-throughput screening of pharmacological compounds.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Richard Pr DELORME, Professor
- Numero di telefono: 0033140034130
- Email: richard.delorme@rdb.aphp.fr
Luoghi di studio
-
-
-
Paris, Francia, 75019
- Hôpital Robert Debré
-
Contatto:
- Delorme Richard Pr Study Coordinator, Professor
- Numero di telefono: 0033 1 40 03 41 30
- Email: richard.delorme@rdb.aphp.fr
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
● For all participants :
-
1) Be Included in the "Genes and Autism" protocol (C07-33 or C16-89).
-
2) Affiliated to the social insurance, Universal Health Coverage or any equivalent system.
→As a Reminder : C07-33 inclusion criteria
● Participants with ASD.
-
1) Autistic patients must meet the diagnostic criteria of DSM-IV [American Psychiatric Association, 1994] and the criteria of ADI-R (Autism Diagnostic Interview-Revised, Lord et al., 1994) and ADOS for autism.
..Or.. Patients with Asperger's syndrome must meet the DSM-IV criteria as well as the ASDI criteria for Asperger's syndrome (Asperger Syndrome Diagnostic Interview, Gillberg et al., 2001) and the ADOS for autism spectrum disorders.
..Or.. Patients with ASD must meet diagnostic criteria of DSM-IV and ADOS criteria for autism spectrum disorders
-
2) Be at least 2 years old, with no upper age limit
-
3) Somatic state compatible with blood test
● Adult controls and adult relatives of controls
-
1) Be between 18 and 65 years old
-
2) Somatic and intellectual state compatible with blood test
● Controls with mental retardation
-
1) Minimum age of 2 yearsIQ < 70Child controls
-
2) Minimum age of 2 years
→As a Reminder : inclusion criteria C16-89
● Probands with ASD
-
1) Meet the diagnostic criteria for ASD of the of DSM-5 [American Psychiatric Association, 2012]. The diagnosis will be based on a consensus between the clinical expertise of expert clinicians, the scores of the Autism Diagnostic Interview-Revised (ADI-R) (Lord et al, 2003) and those of the Autism Diagnosis Observational Scale (ADOS-2) (Lord et al, 1994)
-
2) Be at least 24 months old with no upper age limit
-
3) Somatic state compatible with a blood test
-
4) Affiliation to the Social Insurance
-
5) Signature of informed consent by the applicant or by the holders of parental authority if the subject is a minor or by the guardian if the subject is under guardianship
● Controls wihout ASD
-
1) At least 24 months old
-
2) Somatic and Intellectual state compatible with a blood test
-
3) Affiliation in the Social Insurance
-
4) Signature of informed consent by the subject or by holders of parental authority if the subject is a minor, or by the guardian if the subject is under guardianship
● Relatives of the probands with ASD or of controls without ASD
-
1) At least 24 months old
-
2) Somatic and intellectual state compatible with blood test
-
3) Affiliation to the Social Insurance
-
4) Signature of informed consent by the subject or by the holders of parental authority if the subject is a minor or by the guardian if the subject is under guardianship
Exclusion Criteria:
-
For all participants
-
1) Refusal to have a blood test
-
2) Medical illness (including psychiatric disorder) not yet fully stabilised and making participation in the study impossible
-
3) Person subject to a mesure of lagal protection
-
4) Known serology : VIH+ or VBH+ or VCH+
- As a reminder : exclusion criteria C07-33
-
1) For all participants : Severe Intelectual Deficiency (IQ,35 or developmental age <18 months)
-
2) Controls : Neurological or psychiatric history other than mental retardation
o Psychiatric history, except for mental retardation, assessed using the DIGS (Diagnostic Interview for Genetic Studies, Nurnberger et al., 1994) for adults or the Kiddie-SADS (Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children, Orvaschel et al., 1982)
o History of epileptic episodes
o Immunosuppressive treatment or known immunoinflammatory disease
→As a reminder : exclusion criteria C16-89
-
1) Probands with Autism Spectrum Disorder
o Severe intellectual disability (IQ<35 or developmental age <18 months)
-
2) Controls (neurotypical development)
o Identified intellectual disorder or cognitive developmental disorder
- Personal psychiatric history of schizophrenia, bipolar disorder, substance use disorders (except tobacco), recurrent depression (>2 episodes, lifetime), severe unstabilized anxiety disorder
- History of epilepsy episodes or severe neurological disease
-
3) Relatives of the TSA applicants or controls
- Medical condition (psychiatric or somatic) not compatible with inclusion
-
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Diagnostico
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Altro: Probands with Autism Spectrum Disorder, (N=200).
All subjects included in this study will be drawn from the population of subjects already included in the studies entitled 'Genes and Autism' promoted by Inserm (NCT02628808/C07-33 and NCT04727489/C16-89). Patients are diagnosis ASD according to DSM-V criteria and carry genetic variations known to be associated with autism (whether rare or common). |
Participation in this study requires a single visit per participant. This study only requires a blood sample (5 to 30 minutes) to be taken at the CIC at Robert-Debré Hospital, Paris 19th arrondissement. This blood sample will enable the isolation of peripheral blood mononuclear cells (PBMCs). HIV, HCV and HBV serology will also be performed. |
|
Altro: Controls without Autism Spectrum Disorder
At least, 24 months old (N=150) All subjects included in this study will be drawn from the population of subjects already included in the studies entitled 'Genes and Autism' promoted by Inserm (NCT02628808/C07-33 and NCT04727489/C16-89). |
Participation in this study requires a single visit per participant. This study only requires a blood sample (5 to 30 minutes) to be taken at the CIC at Robert-Debré Hospital, Paris 19th arrondissement. This blood sample will enable the isolation of peripheral blood mononuclear cells (PBMCs). HIV, HCV and HBV serology will also be performed. |
|
Altro: Relatives of the probands with ASD
Adult relatives of controls with ASD (N=100) All subjects included in this study will be drawn from the population of subjects already included in the studies entitled 'Genes and Autism' promoted by Inserm (NCT02628808/C07-33 and NCT04727489/C16-89). |
Participation in this study requires a single visit per participant. This study only requires a blood sample (5 to 30 minutes) to be taken at the CIC at Robert-Debré Hospital, Paris 19th arrondissement. This blood sample will enable the isolation of peripheral blood mononuclear cells (PBMCs). HIV, HCV and HBV serology will also be performed. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Isolation of peripheral blood mononuclear cells (PBMCs)
Lasso di tempo: Inclusion visit
|
Blood sample to be taken from individuals with ASD, a population of relatives, and a population of controls. |
Inclusion visit
|
Collaboratori e investigatori
Investigatori
- Direttore dello studio: Thomas Pr Bourgeron, Professor, Institut Pasteur
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- C22-14
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .